Leila Vania,Gavin Morris,Tyrone C Otgaar et al.
Leila Vania et al.
Introduction: The ubiquitously expressed 37 kDa/67 kDa high-affinity laminin receptor (laminin receptor precursor/laminin receptor, LRP/LR) is a protein found to play several roles within cells. The receptor is located in the nucleus, cytos...
Technological prospection: patents mapping involving compounds for the treatment of L-DOPA-induced dyskinesias [0.03%]
技术探测：涉及左旋多巴诱发运动障碍治疗化合物的专利布局分析映射
Sheilla Da Silva Barroso,Lorenna Emília Sena Lopes,Klebson Silva Santos et al.
Sheilla Da Silva Barroso et al.
Introduction: Parkinson's disease (PD), is a disorder debilitant characterized by the reduction of nigrostriatal dopaminergic neurons within the midbrain, specifically in the substantia nigra pars compacta, which results for the dopamine (D...
Fibroblast growth factor receptor inhibitors: patent review (2015-2019) [0.03%]
成纤维细胞生长因子受体抑制剂专利回顾（2015-2019）
Giuseppe Marseglia,Alessio Lodola,Marco Mor et al.
Giuseppe Marseglia et al.
Introduction: fibroblast growth factor receptors (FGFRs) are a family of tyrosine-kinase receptors whose signaling cascade regulates cellular proliferation, differentiation, and survival. Deregulation of the FGFR pathway is recognized as a ...
PI3Kδ inhibitors for the treatment of cancer: a patent review (2015-present) [0.03%]
PI3Kδ抑制剂在癌症治疗中的应用专利回顾(2015-今)
Yifan Feng,Xiaochuan Cu,Minhang Xin
Yifan Feng
Introduction: PI3Kδ is an important subtype of PI3K kinases, which is mainly expressed in leukocytes and plays an important role in the proliferation, differentiation, maturation and self-reaction of B cells. It is an effective target in t...
Bispecific anti-OX40/CTLA-4 antibodies for advanced solid tumors: a patent evaluation of WO2018202649 [0.03%]
评估WO2018202649有关治疗实体瘤的抗OX40 / CTLA专利申请说明书评估双特异性抗体
Martin Perez-Santos,Maricruz Anaya-Ruiz,Irma Herrera-Camacho et al.
Martin Perez-Santos et al.
Introduction: OX40 is a potent costimulatory receptor of the immune response in various types of cancer and has been used as a target for the generation of agonists of its function. Authors of WO2018202649 patent propose a method to eradica...
An update on liposomes in drug delivery: a patent review (2014-2018) [0.03%]
药物递送中的脂质体研究进展：2014-2018年专利回顾
Mazen M El-Hammadi,José L Arias
Mazen M El-Hammadi
Introduction: Pharmacotherapy is limited by the inefficient drug targeting of non-healthy cells/tissues. In this pharmacological landscape, liposomes are contributing to the impulse given by Nanotechnology to optimize drug therapy. Areas co...
Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019 [0.03%]
二氧化碳阴离子酶抑制与青光眼的治疗：2013-2019年文献及专利回顾
Claudiu T Supuran,Abdulmalik Saleh Alfawaz Altamimi,Fabrizio Carta
Claudiu T Supuran
Introduction: Glaucoma affects more than 70 million people worldwide. One of the major therapeutic options for its management is based on the inhibition of the metalloenzyme carbonic anhydrases (CAs, EC 4.2.1.1). CA inhibitors (CAIs) dimini...
Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2016-2019) [0.03%]
新型尿酸转运蛋白1(URAT1)抑制剂专利的近期研究进展综述(2016-2019)
Yue Dong,Tong Zhao,Wei Ai et al.
Yue Dong et al.
Introduction: Human urate transporter 1 (URAT1), which is an influx transporter protein, is located at the apical surface of renal tubular cells and presumed to be the major transporter responsible for the reabsorption of urate from blood. ...
Emanuela Berrino,Claudiu T Supuran
Emanuela Berrino
Introduction: Glaucoma is a group of progressive optic neuropathies in which elevated intraocular pressure (IOP) as a consequence of an increased aqueous humor (AH) outflow resistance, is the main and only clinically modifiable risk factor ...
Steven Fletcher
Steven Fletcher
Introduction: Myeloid cell leukemia-1 (MCL-1) is an anti-apoptotic member of the B-cell lymphoma-2 (BCL-2) family of proteins that regulates apoptosis. Elevated levels of MCL-1 contribute to tumorigenesis and resistance, not only to convent...